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Background Non-muscle invasive bladder cancer
(NMIBC) is a locally recurring disease for which patients
undergo long term surveillance following initial diagno-
sis. CALIBER is a multicentre phase II feasibility study
comparing intravesical chemotherapy (chemoresection)
with surgery (standard of care) in patients with recurrent
low risk NMIBC (2:1 chemoresection:surgery random-
isation). The primary aim is to assess complete response* Correspondence: CALIBER-icrctsu@icr.ac.uk
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bility of recruitment to a larger randomised phase III trial.
It was anticipated that patient recruitment would be chal-
lenging due to the need to identify potential participants at
the time of recurrence prior to treatment, complex risk
stratification criteria and varied treatment pathways across
participating sites. As such we developed recruitment aids
with the aim of raising awareness amongst potential partic-
ipants, ensuring site staff remain aware of the trial and pro-
moting effective liaison between site staff when suitable
patients are identified.
Methods From the outset of the trial, ethics approved
short patient information leaflets and posters have been
available to highlight the trial to patients attending surveil-
lance visits. A staff poster was also provided to raise aware-
ness amongst staff conducting surveillance. A CALIBER
specific risk calculation tool was introduced in March 2016
as an aid to assess eligibility. We surveyed 34 participating
centres about their use of these aids and their use of the
tools was compared to their average recruitment.
Results Responses were received from 26/34 centres.
25/26 (96%) are using at least one of the short patient
information leaflet, patient poster, clinician poster or
eligibility. Average monthly recruitment does not appear
to increase with increased use of the tools, with a median
recruitment of 0.21 for the 8/26 (31%) sites using two
tools and 0.03 for the 6/26 (23%) sites using all four. Since
distributing the CALIBER risk calculator, the number of
eligibility queries received by the coordinating clinical
trials unit has substantially decreased. Initial feedback
from centres suggests it is a useful tool for local pre-
screening. Centres are advised to print the Trials 2017,
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tools on recruitment could not be confirmed as most
have been available since the trial commenced. The re-
duction in eligibility queries since introduction of the re-
currence calculation tool may be a result of increased
centre experience. In addition, the use of tools may be
confounded with factors such as centre size and
frequency of patient screening for the trial.
Conclusions With provision of targeted recruitment
aids, centre staff training and ongoing support from the
coordinating clinical trials unit, potential barriers to re-
cruitment in a trial with challenging patient identifica-
tion pathways and complex eligibility criteria can be
managed effectively. However there is no obvious in-
crease in recruitment with increased use of recruitment
aids. In order to robustly evaluate the impact of recruit-
ment aid interventions they should be introduced in a
controlled manner to facilitate assessment of within and
between centre pre- and post- intervention accrual rates.
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